Group 1: Financial Performance - The company's revenue for the first half of 2025 is expected to grow by approximately 12% year-on-year, primarily due to a decline in sales of traditional Chinese medicine products compared to the previous year [1] - The net cash flow from operating activities is projected to be between 270 million and 290 million CNY, an improvement from 215.35 million CNY in the same period last year [3] Group 2: Cost Management - The company implements measures such as lean management, cost reduction, and comprehensive budget management to enhance expense control and improve efficiency [1] - Sales expense ratio is expected to fluctuate based on marketing strategies and product promotion, with a historical decline due to centralized procurement [2] Group 3: Market Expansion Strategies - The company plans to strengthen strategic partnerships with leading pharmacy chains and enhance patient education and promotion activities [4] - Digital marketing initiatives will be advanced through O2O strategies to capture the young consumer market [4] - Collaboration with Zhejiang University aims to develop innovative health products leveraging AI technology [5] Group 4: Research and Development - The company is focused on developing innovative traditional Chinese medicine, with several projects in clinical and preclinical stages [5] - Ongoing research includes secondary development of existing products and expanding indications for current medications [5]